Comparer des méthodes

	Score d'évaluation de l'incapacité liée à la migraine (MIDAS)	Quality of Life in Epilepsy-89 (QOLIE-89)	Échelle de qualité de vie spécifique à l'AVC (SS-QoL)
Domaine	Neurologie	Neurologie	Neurologie
Famille	Process / pipeline	Process / pipeline	Process / pipeline
Année d'origine	1999	1995	1999
Auteur d'origine	William F. Stewart, Johns Hopkins University	Orrin Devinsky, NYU	Lee S. Williams, Indiana University
Type	Self-report questionnaire	Self-report questionnaire	Self-report questionnaire
Source fondatrice	Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (1999). Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire. Neurology, 53(Suppl 3), S23-S28.	Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.	Williams, L. S., Weinberger, M., Harris, L. E., Clark, D. O., & Biller, J. (1999). Development of a Stroke-Specific Quality of Life Scale. Stroke, 30(7), 1362-1369.
Alias	MIDAS Scale, Migraine Disability Assessment	QoLIE-89	Stroke-Specific QoL, SS-QOL
Apparentées	2	3	4
Résumé	The MIDAS is a brief, five-item self-report questionnaire that quantifies migraine-related disability by measuring days lost from work, school, household activities, and family/social activities over a 3-month period. Introduced by Stewart and colleagues in 1999, it is the most widely used measure of migraine burden in clinical practice and research. MIDAS directly translates migraine frequency and severity into functional impact (lost productivity, lost days), enabling healthcare providers and patients to understand the true disability burden of migraines.	The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy. Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.	The SS-QoL is a disease-specific quality-of-life instrument designed to capture the multidimensional impact of stroke on survivors' functional and emotional well-being. Developed by Williams and colleagues in 1999, this 49-item scale addresses stroke-specific concerns including language, cognition, mobility, and emotional functioning. It is a gold-standard instrument for stroke outcome research and routine clinical monitoring of post-stroke recovery.